SCHEMBL22609263

SCHEMBL22609263

CCOC(=O)c1nnccc1Nc1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ MAPT P10636 4/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ CASP3 P42574 1/20 0.48
▸ TRPV1 Q8NER1 1/20 0.48
▸ SENP7 Q9BQF6 1/20 0.48
▸ TP53 P04637 2/20 0.47
▸ POLB P06746 1/20 0.46
▸ RAB9A P51151 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ ILK Q13418 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ HPGD P15428 2/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23486570 0.87 ILK (0.57) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL22609234 0.81 ALDH1A1 (0.49) LMNAKDM4EALDH1A1MAPTMEN1
SCHEMBL22609254 0.79 DHODH (0.46) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL25314681 0.79 TTR (0.43) KDM4EALDH1A1MAPTRAB9ANPC1
SCHEMBL3630708 0.76 KDM4E (0.67) LMNAKDM4EALDH1A1MAPTMEN1
SCHEMBL22609340 0.75 MAPT (0.46) LMNAKDM4EALDH1A1MAPTMEN1
SCHEMBL22609328 0.74 ILK (0.77) LMNAKDM4EALDH1A1MAPTMEN1
SCHEMBL2829177 0.73 KDM4E (0.54) LMNAKDM4EALDH1A1MAPTMEN1
SCHEMBL353413 0.73 CYP1A2 (0.44) LMNAKDM4EALDH1A1MAPTKMT2A
SCHEMBL5545753 0.72 LMNA (0.46) LMNAKDM4EALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS LMNA 3881/4885KDM4E 3616/4885ALDH1A1 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback